Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
Gilead is renowned for its antiviral drugs, but who knew about its interesting oncology pipeline?
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
While Gilead (GILD +0.00%) is often thought of as king in the HIV space and is leading the race for successful interferon-free hepatitis C treatment with some astounding cure rates in clinical trials, its recent announcement that it will acquire YM BioSciences (NYSEMKT: YMI) highlights a lesser-known direction for the company: its oncology pipeline. In this video, Motley Fool health care analyst David Williamson discusses what the acquisition means for Gilead and its aspirations in the oncology field.